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Background:  Dengue  disease  is a major  public  health  problem  across  the  Asia-Paciﬁc  region  for  which
there  is no licensed  vaccine  or treatment.  We  evaluated  the  safety  and  immunogenicity  of  Phase  III lots
of a  candidate  vaccine  (CYD-TDV)  in  children  in  Malaysia.
Methods:  In this  observer-blind,  placebo-controlled,  Phase  III study,  children  aged  2–11  years  were
randomized  (4:1)  to  receive  CYD-TDV  or  placebo  at  0, 6 and  12  months.  Primary  endpoints  included
assessment  of  reactogenicity  following  each  dose,  adverse  events  (AEs)  and  serious  AEs  (SAEs)  reported
throughout  the  study,  and  immunogenicity  expressed  as  geometric  mean  titres  (GMTs)  and distribution
of dengue  virus  (DENV)  neutralizing  antibody  titres.
Results:  250  participants  enrolled  in  the  study  (CYD-TDV:  n  =  199;  placebo:  n  = 51).  There  was  a  trend
for reactogenicity  to  be  higher  with  CYD-TDV  than  with  placebo  post-dose  1 (75.4%  versus  68.6%)  and
post-dose  2  (71.6%  versus  62.0%)  and  slightly  lower  post-dose  3  (57.9%  versus  64.0%).  Unsolicited  AEs
declined  in  frequency  with  each  subsequent  dose  and  were  similar  overall  between  groups (CYD-TDV:
53.8%;  placebo:  49.0%).  Most  AEs  were  of  Grade  1  intensity  and  were  transient.  SAEs  were  reported  by
5.5%  and  11.8%  of  participants  in  the  CYD-TDV  and  placebo  groups,  respectively.  No  deaths  were  reported.
Baseline  seropositivity  against  each  of  the  four  DENV  serotypes  was  similar  between  groups,  ranging  from
24.0%  (DENV-4)  to 36.7%  (DENV-3).  In  the  CYD-TDV  group,  GMTs  increased  post-dose  2  for  all  serotypes
compared  with  baseline,  ranging  from  4.8 (DENV-1)  to 8.1-fold  (DENV-3).  GMTs  further  increased  post-
dose  3  for  DENV-1  and  DENV-2.  Compared  with  baseline,  individual  titre  increases  ranged  from  6.1-fold
(DENV-1)  to 7.96-fold  (DENV-3).
Conclusions:  This  study  demonstrated  a  satisfactory  safety  proﬁle  and  a balanced  humoral  immune
response  against  all four  DENV  serotypes  for CYD-TDV  administered  via  a three-dose  regimen  to children
in Malaysia.           
 Trial registration: The trial is registered on ClinicalTrials.gov.: National Clinical
rials Identiﬁer (NCT ID): NCT01254422.
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264-410X     ©  2013 The Authors. Published by Elsevier Ltd. 
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1. Introduction
Open access under CC BY license.Dengue disease is caused by dengue virus (DENV) serotypes
(1–4) and is transmitted mainly by Aedes aegypti mosquitoes [1].
Dengue disease is classiﬁed as with or without warning signs, or
(L. Zhou), Alain.Bouckenooghe@sanoﬁpasteur.com (A. Bouckenooghe),
Denis.Crevat@sanoﬁpasteur.com (D. Crevat), Yanee.Hutagalung@sanoﬁpasteur.com
(Y. Hutagalung).
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evere dengue disease [2]. Infection with one DENV serotype usu-
lly imparts immunity to that serotype [3]. No licensed vaccine
r treatment for dengue disease currently exists. Prevention relies
n individual protection and vector control measures, which have
imited effectiveness [1].
The Asia-Paciﬁc region is considered the global epicentre of
he disease, with ∼1.8 billion people at risk [4]. Dengue disease is
ndemic in Malaysia [5–7] and its incidence has increased dramat-
cally, from <20/100,000 in the 1970s [7] to >150/100,000 in 2010
8], with an increased prevalence in adults relative to children (the
ain target population for potential dengue disease vaccines) and
everal changes in serotype distributions and increases in disease
everity [7–13].
Increasing disease burden has spurred the development of
otential dengue vaccines [14]. One live-attenuated tetravalent
engue vaccine (CYD-TDV, Sanoﬁ Pasteur, Lyon, France), con-
ains four recombinant viruses engineered with DENV1–4. Each
YD-TDV virus expresses dengue pre-membrane and envelope
roteins of the associated serotype, and the non-structural and
apsid proteins of the attenuated Yellow Fever (YF-17D) vaccine
irus [15–19]. In Phase I and II studies, CYD-TDV elicited balanced
eutralizing antibody responses against DENV1–4 and was well tol-
rated [20–28]. In a large Phase IIb study in Thai schoolchildren,
YD-TDV appeared to be efﬁcacious against three of the four DENV
erotypes and was well tolerated over 2 years of follow-up with no
afety concerns [29].
The primary objectives of our study were to evaluate the safety
nd immunogenicity of CYD-TDV in children aged 2–11 years in
alaysia. This is the ﬁrst Phase III CYD-TDV study to be reported
hat uses Phase III lots (manufactured by large-scale production
rocesses) in an area where dengue disease is endemic. Addition-
lly, one of the study sites was located in the Sarawak state of
alaysia, where Japanese Encephalitis (JE) is endemic and JE vac-
ination is routine.
. Methods
.1. Study design and participants
This multicentre, randomized, observer-blind, placebo-
ontrolled, Phase III study was conducted between December
010 and August 2012 at four sites in Malaysia: Kuala Lumpur,
poh (Perak state), Seremban (Negeri Sembilan state) and Kuching
Sarawak state). The methodology was similar to that of previous
YD-TDV Phase II studies [22,26] but used Phase III vaccine lots.
ealthy children (aged 2–11 years) were assigned randomly to
wo groups (4 CYD-TDV: 1 placebo). All participants received
hree injections at 0, 6 and 12 months and were followed up for 6
onths post-dose 3 to assess safety.
Participants were recruited by the study investigators, sub-
nvestigators and research nurses. Randomization was  performed
y study-site personnel via an Interactive Voice Recognition System
IVRS), using a permuted block method with stratiﬁcation by cen-
re and age. A double randomization system separated treatment
llocation from doses dispensed. The IVRS was used in a blind man-
er to ensure a balanced distribution of the number of participants
ith a history of JE vaccination, known JE infection or dengue dis-
ase infection in each age group (2–5 and 6–11 years) of the study
roups, based on medical records or parents’ recollection.
Girls of childbearing age were checked for pregnancy (urine
est) and required to abstain from sexual intercourse or use
ontraception from four weeks before the ﬁrst dose until four
eeks after the last dose. Exclusion criteria included prior or
urrent participation in another clinical study; receipt of blood
r blood-derived products in the previous 3 months that could (2013) 5814– 5821 5815
interfere with immunogenicity assessments; hypersensitivity to
the vaccine components; and vaccination with any other vaccine
(except for pandemic inﬂuenza) in the 4 weeks prior to enrolment.
Contraindications to receiving subsequent vaccinations included
signiﬁcant allergic reaction (AR), serious adverse event (SAE) or
ongoing adverse event (AE) related to the previous vaccination.
2.2. Ethical considerations
The study was conducted in accordance with the Declaration of
Helsinki (Seoul revision), with Good Clinical Practice (deﬁned by
the International Conference on Harmonisation), and with appli-
cable national and local requirements. The Medical Research and
Ethics Committee of the Ministry of Health of Malaysia approved
the protocol. Each investigator obtained approval from an indepen-
dent ethics committee or institutional review board. Participants’
parents or legal representatives provided written informed con-
sent and children aged ≥7 years signed an assent form. The trial is
registered on ClinicalTrials.gov. (NCT01254422).
2.3. Study procedures
Blood samples were taken prior to vaccination, to assess
ﬂavivirus (FV) serostatus (dengue disease or JE) using plaque reduc-
tion neutralization tests (PRNT50) [30,31], and 28 days post-dose 2
and 3 to assess immunogenicity.
2.4. Vaccine
CYD-TDV Phase III lots were manufactured using a large-scale
production process. CYD-TDV vaccine details have been published
[17–19]. CYD-TDV comprises a powder and solvent for suspension
and must be stored at 2–8 ◦C. Each 0.5 ml  dose of reconstituted
vaccine contained approximately 5 ± 1 log10 cell-culture infec-
tious dose 50% (CCID50) of each live, attenuated, recombinant CYD
serotypes 1–4 (batch numbers: dose 1: S4316F02 and D0822; dose
2: S4316F08 and D1148; dose 3: S4316F14 and D1148). Placebo
was  0.9% saline solution (batch numbers: dose 1: E5594F04; dose 2:
E5594F08; dose 3: E5594F06). Vaccinations were by subcutaneous
injection in the deltoid region of the upper arm using a 25G × 5/8 in.
(0.5 mm  × 16 mm)  needle.
2.5. Primary endpoints
2.5.1. Safety and reactogenicity
Safety and reactogenicity data (graded in severity from 1 to
3) were collected after each dose: immediate AEs within 30 min;
solicited injection-site reactions within 7 days; solicited systemic
reactions within 14 days; and unsolicited AEs within 28 days of
vaccination. SAEs and suspected dengue disease cases requiring
hospitalization were monitored throughout the study. An indepen-
dent data monitoring committee reviewed all SAEs.
2.5.2. Immunogenicity
Neutralizing antibody levels against DENV1–4 were assessed
28 days post-dose 2 and 3 using a PRNT50 compliant with WHO
guidelines [30,31] and expressed as geometric mean titres (GMTs)
and seropositivity rates (percentage of participants with titres
≥10 1/dil). Distribution of individual titres at enrolment and post-
dose 2 and 3 of CYD-TDV or placebo was  analyzed using reverse
cumulative distribution curves.2.6. Secondary endpoints
CYD-TDV safety and immunogenicity assessments were
stratiﬁed according to baseline FV-serostatus (seropositive or
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eronegative for dengue disease or JE) and by age (2–5 and 6–11
ears). Pre-vaccination, post-dose 2 and post-dose 3 GMTs were
lso analyzed according to FV-serostatus at baseline (seropositive
r seronegative for dengue disease and JE).
.7. Statistical methods
.7.1. Sample size and study populations
With a planned sample size of 250 participants (CYD-TDV:
 = 200; placebo: n = 50) and assuming a drop-out rate of 15%,
he probability of observing a common AE after three vaccina-
ions was 100% and 82% if the incidence of the AE was 5% and
%, respectively. Of the 200 CYD-TDV recipients, 60–140 were
xpected to be FV-seropositive at baseline. Based on a variability
f 0.7 log10 for the PRNT50 assay, the power to detect differences
f ≥0.4 in log10 GMTs between FV-seropositive and -seronegative
articipants and between age groups was >90%. The popula-
ions analyzed included a Safety Analysis Set (SAS, participants
eceiving at least one dose of study vaccine) and a Full Anal-
sis Set (FAS, participants receiving at least one dose of study
accine, with a valid post-vaccination serology result). Further
nalyses were conducted stratiﬁed by FV-serostatus and by age
roup.
Enrolled: n=
Randomized to
CYD-TDV group
n=199
Received CYD-TDV
at visit 01:
n=199 (100%)
Received CYD-TDV
at visit 03:
n=197 (99%)
Received CYD-TDV
at visit 05:
n=196 (98.5%)
Completed vaccination
phase, visit 06
n=196 (98.5%)
Did not complete vaccination phase: n=3 (1.5%)
• Adverse event: n=1 (0.5%);
• Lost to follow-up: n=1 (0.5%);
• Non-compliance with protocol: n=1 (0.5%) 
D
•
Discontinued
n=2 (1%)
Discontinued
n=1 (0.5%)
ig. 1. Study ﬂow chart: progress of participants through the study. Reasons for with
onjunctivitis), one was  lost to follow-up after the ﬁrst vaccination, and one did not comp
roup,  one participant experienced a SAE (right VII nerve paralysis) after the ﬁrst vaccina (2013) 5814– 5821
2.7.2. Statistical analyses
Analyses were descriptive with no hypothesis tested. For the
main parameters, 95% conﬁdence intervals of point estimates were
calculated using a normal approximation for quantitative data and
exact binomial distribution (Clopper–Pearson method) for propor-
tions [32,33]. Analyses were conducted with SAS software, version
9.1 or above (SAS Institute, Cary, NC, USA).
3. Results
The ﬁrst participant was enrolled on 2 December 2010 and the
last participant’s 6 month follow-up visit was  14 August 2012. We
enrolled 250 participants in the study (CYD-TDV: n = 199; placebo:
n = 51), of whom 196 (98.5%) and 50 (98%) in the CYD-TDV and
placebo group, respectively, completed the vaccination phase and
were included in the FAS (n = 246, Fig. 1).
In the SAS (n = 250), 55.8% of participants in the CYD-TDV group
and 60.8% in the placebo group were FV-seropositive (seropositive
for DENV and/or JE). In the CYD-TDV and placebo groups, 49.7% and
52.0% of participants were aged 2–5 years, respectively. In the CYD-
TDV group, 57.3% of children aged 2–5 years were FV-seropositive
and 42.7% were FV-seronegative and in children aged 6–11 years,
54.0% were FV-seropositive and 46.0% were FV-seronegative.
250
Randomized to
placebo group
n=51
Received placebo
at visit 01:
n=51 (100%)
Received placebo
at visit 03:
n=50 (98%)
Received placebo
at visit 05:
n=50 (98%)
id not complete vaccination phase: n=1 (2%)
 Serious adverse event: n= 1 (2%)
Discontinued
n=1 (2%)
Completed vaccination
phase, visit 06
n=50 (98%)
drawal: In the CYD-TDV group, one participant withdrew due to an AE (allergic
ly with the protocol by refusal of a blood sample before injection 3. In the placebo
tion, which was assessed by the investigator to be related to treatment.
A.-S. HSS et al. / Vaccine 31 (2013) 5814– 5821 5817
Table  1
Demographic and baseline characteristics of participants: Safety Analysis Set (all participants and categorized according to ﬂavivirus serostatus at baseline and stratiﬁed by
age  [2–5 and 6–11 years]).
CYD-TDV Placebo
All FV-seropositive at baseline FV-seronegative at baseline Age 2–5 years Age 6–11 years
N 199 111 88 99 100 51
Sex,  n (%)
Male 96 (48.2) 51 (45.9) 45 (51.1) 51 (51.5) 45 (45.0) 32 (62.7)
Female 103 (51.8) 60 (54.1) 43 (48.9) 48 (48.5) 55 (55.0) 19 (37.3)
Age  (years)
Mean (±SD) 6.4 (2.8) 6.5 (2.9) 6.2 (2.7) 4.0 (1.2) 8.7 (1.7) 6.5 (3.0)
Range  2.0–11.9 2.1–11.9 2.0–11.6 2.0–5.9 6.0–11.9 2.1–11.8
Height (cm)
Mean (±SD) 113.7 (18.1) 114.4 (19.1) 112.8 (16.9) 99.5 (10.6) 127.8 (11.9) 115.7 (19.4)
Range  78.0–157.0 78.0–153.0 81.0–157.0 78.0–121.0 104.0–157.0 84.0–158.0
Weight (kg)
Mean (±SD) 21.9 (10.6) 22.9 (11.5) 20.7 (9.2) 15.6 (4.7) 28.2 (11.0) 22.7 (10.8)
Range  8.9–77.0 9.0–77.0 8.9–61.5 8.9–37.6 15.4–77.0 11.0–54.9
Body  mass index (kg/m2)
Mean (±SD) 16.2 (3.6) 16.6 (3.6) 15.7 (3.5) 15.6 (2.9) 16.8 (4.0) 16.2 (3.8)
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CRange  11.7–34.8 12.1–34.7 11.7–
V, ﬂavivirus; n, number of participants; SD, standard deviation.
Baseline demographic characteristics were similar between
roups and in the FV-serostatus subsets (Table 1). However, base-
ine GMTs against DENV1–4 were slightly higher in those aged 6–11
ears than in those aged 2–5 years (Table 2). The majority of par-
icipants were of Asian origin (n = 248) and two participants were
f Asian/Caucasian origin.
.1. Safety and reactogenicity
The proportion of participants reporting solicited reactions
total and injection site and systemic reactions) was similar in the
YD-TDV (89.4%) and placebo (94.1%) groups (Table 3). However,
here was a trend for slightly higher reactogenicity with CYD-TDV
ompared with placebo post-dose 1 and 2 (75.4% versus 68.6% and
1.6% versus 62.0%, respectively) and slightly lower reactogenicity
n the CYD-TDV group compared with placebo post-dose 3 (57.9%
ersus 64.0%, Fig. 2).
able 2
eometric mean titres (GMTs) for dengue serotype-speciﬁc plaque reduction neutraliza
njections of CYD-TDV or placebo: Full Analysis Set for all participants and stratiﬁed acco
CYD-TDV group GMT  1/dil (95% CI) 
All (n = 196) FV-seropositive at
baseline (n = 109)
FV-seronegative 
baseline (n = 87)
DENV-1
Pre-vacc 15.3 (11.5; 20.4) 37.5 (24.0; 58.6) 5.0 (NC) 
Post-dose 2 119 (90.7; 155) 248(171; 361) 47.1 (35.3; 62.9
Post-dose 3 151(121; 188) 247(178; 343) 81.6 (66.3; 101)
DENV-2
Pre-vacc 15.9 (11.8; 21.3) 39.9 (25.2; 63.1) 5.0 (NC) 
Post-dose 2 160(127; 203) 306(221; 424) 71.4 (55.4; 92.1
Post-dose 3 180(146; 221) 292(217; 395) 97.5 (77.5; 123)
DENV-3
Pre-vacc 15.6 (12.3; 19.9) 38.8 (27.3; 55.4) 5.0 (NC) 
Post-dose 2 196(163; 235) 296(230; 381) 116 (92.6; 146) 
Post-dose 3 193(161; 231) 287(219; 376) 117 (97.4; 141) 
DENV-4
Pre-vacc 9.92 (8.17; 12.0) 17.1 (12.5; 23.5) 5.0 (NC) 
Post-dose 2 110 (88.9; 136) 152(115; 201) 73.3 (53.7; 100)
Post-dose 3 114 (97.0; 134) 155(125; 191) 78.0 (62.0; 98.1
I, conﬁdence interval; FV, ﬂavivirus; GMT, geometric mean titre; n, number of participan11.7–34.8 12.1–34.7 12.0–32.5
The number of solicited systemic reactions decreased after each
injection in both groups. Solicited injection site reactions in the
CYD-TDV group tended to be more frequent post-dose 2 compared
with post-dose 1 and less frequent post-dose 3. In the placebo
group, solicited injection site reactions were more frequent post-
dose 2 and 3 than post-dose 1 (Fig. 2).
Most solicited injection site reactions and systemic reactions
were Grade 1 and lasted <3 days. The most frequently reported
injection site reactions were pain (CYD-TDV: 69.3%; placebo:
56.9%), erythema (46.7% and 49.0%) and swelling (38.7% and 35.3%).
In both study groups, malaise (CYD-TDV: 54.3%; placebo: 41.2%)
and headache (52.3% and 39.2%) were the most frequently reported
solicited systemic reactions, followed by asthenia, myalgia and
fever. Fever was  the most commonly reported Grade 3 reaction
in both groups (CYD-TDV: 6.6%; placebo: 3.9%), and approximately
half of these reported concomitantly with intercurrent infections
(Supplementary table S1).
tion tests (PRNT50) antibodies before vaccination and 28 days after two and three
rding to ﬂavivirus serostatus at baseline and age (2–5 years and 6–11 years).
Placebo group GMT
1/dil (95% CI)
at Age 2–5 years
(n = 96)
Age 6–11 years
(n = 100)
All (n = 50)
10.4 (7.51; 14.5) 22.2 (14.1; 34.8) 18.6 (9.69; 35.8)
) 95.9 (69.0; 133) 146 (95.4; 222) 21.0 (10.6; 41.9)
 117 (91.2; 151) 192(136; 272) 18.9 (9.94; 35.8)
11.1 (7.79; 15.7) 22.5 (14.2; 35.6) 18.6 (10.0; 34.5)
) 138(106; 181) 185(126; 272) 17.9 (9.91; 32.2)
 158(125; 201) 203(144; 285) 16.3 (9.59; 27.7)
12.1 (8.97; 16.3) 20.0 (13.7; 29.2) 15.9 (9.57; 26.5)
167(134; 207) 228(170; 306) 15.9 (9.27; 27.4)
168(136; 208) 220(164; 295) 16.3 (9.81; 27.0)
8.28 (6.44: 10.6) 11.8 (8.79: 15.8) 12.3 (7.96; 19.0)
 101 (75.8: 134) 119 (87.0: 164) 13.3 (7.94; 22.1)
) 105 (86.0: 129) 123 (95.7: 159) 10.9 (7.34; 16.2)
ts; NC, not calculated.
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Table 3
Overview of safety data up to 28 days after any injection: Safety Analysis Set.
Participants experiencing at least one of: CYD-TDV group (n = 199) Placebo group (n = 51)
n % 95% CI n % 95% CI
Solicited reaction 178/199 89.4 (84.3; 93.3) 48/51 94.1 (83.8; 98.8)
Solicited injection site reaction 163/199 81.9 (75.8; 87.0) 40/51 78.4 (64.7; 88.7)
Solicited systemic reaction 141/199 70.9 (64.0; 77.1) 37/51 72.5 (58.3; 84.1)
Unsolicited AE 107/199 53.8 (46.6; 60.8) 25/51 49.0 (34.8; 63.4)
Unsolicited non-serious AE 105/199 52.8 (45.6; 59.9) 20/51 39.2 (25.8; 53.9)
Unsolicited AR 22/199 11.1 (7.1; 16.3) 5/51 9.8 (3.3; 21.4)
Unsolicited non-serious AR 22/199 11.1 (7.1; 16.3) 4/51 7.8 (2.2; 18.9)
AE  leading to study discontinuationa 1/199 0.5 (0.0; 2.8) 1/51 2.0 (0.0; 10.4)
SAEb 11/199 5.5 (2.8; 9.7) 6/51 11.8 (4.4; 23.9)
AE, adverse event; AR, allergic reaction; CI, conﬁdence interval; n, number of participants; SAE, serious adverse event.
s
a
r
t
I
u
p
l
9
p
g
A
i
n
d
t
p
(
e
p
4
3
d
T
a
s
3
t
p
t
b
4
b
T
9
r
m
w
t
c
ba Identiﬁed in the termination form as SAE or other AE.
b Includes SAEs collected up to after the third injection analysis.
The proportion of participants experiencing unsolicited AEs was
imilar between groups overall (CYD-TDV: 53.8%; placebo: 49.0%)
nd post-dose 1 and 2 (30.7% and 27.5%; and 26.9% and 24.0%,
espectively, Table 3 and Fig. 2), and slightly higher with CYD-TDV
han with placebo post-dose 3 (CYD-TDV: 22.4%; placebo: 14.0%).
nfections and infestations were most frequently reported, with
pper respiratory tract infections predominant (CYD-TDV: 13.8%;
lacebo: 9.8%). The proportion of participants experiencing unso-
icited ARs was similar between groups (CYD-TDV: 11.1%; placebo:
.8%). Injection site induration was the most frequent AR. The pro-
ortions of both unsolicited AEs (Fig. 2) and unsolicited ARs were
enerally lower after each injection for both groups (unsolicited
Rs: CYD-TDV: 7.5%, 2%, 2.6%; placebo: 7.8%, 2%, 0%). Five partic-
pants experienced Grade 1 rash episodes post-dose 1 (CYD-TDV:
 = 3; placebo: n = 1), or post-dose 2 (CYD-TDV: n = 1) lasting ≤6
ays.
Most unsolicited AEs and ARs were non-serious and did not lead
o study discontinuation (Table 3). SAEs were reported by 5.5% of
articipants in the CYD-TDV group and 11.8% in the placebo group
Table 3). All SAEs were assessed as unrelated to study vaccine,
xcept for an SAE of VII nerve paralysis in the placebo group. This
articipant did not receive any further vaccinations and recovered
 months later. No deaths were reported.
.1.1. Safety and reactogenicity by baseline FV-serostatus and age
An analysis by subset showed that safety and reactogenicity
ata were not markedly affected by FV-serostatus or age (Fig. 2).
he decrease in the incidence of systemic reactions post-dose 3
ppeared more marked in the FV-seropositive group than the FV-
eronegative group.
.2. Immunogenicity
Baseline seropositivity against DENV1–4 was similar in both
reatment groups (CYD-TDV: 31.1%, 27.6%, 36.7% and 24.0%;
lacebo: 32.0%, 30.0%, 36.7% and 30.0%, for DENV1–4, respec-
ively). A large proportion of participants were seropositive at
aseline for at least one DENV serotype (CYD-TDV: 44.9%; placebo:
8%). A small proportion of participants were seropositive at
aseline for JE only (CYD-TDV: 10.7%; placebo: 13.7%). In the CYD-
DV group, pre-vaccination GMTs against DENV1–4 ranged from
.92 1/dil (DENV-4) to 15.9 1/dil (DENV-2). Baseline seropositivity
ates against DENV1–4 differed between age groups in both treat-
ent groups, being higher in children aged 6–11 years compared
ith those aged 2–5 years (Supplementary table S2). Similarly in
he CYD-TDV group, GMTs were higher in children aged 6–11 years
ompared with children aged 2–5 years (Table 2). When stratiﬁed
y FV serostatus, GMTs were higher in those aged 6–11 years thanin those aged 2–5 years in participants who were FV-seropositive
at baseline (Supplementary table S3).
Robust immune responses were reported after vaccination with
CYD-TDV regardless of FV-serostatus (Table 2). The geometric mean
fold rise of individual antibody titres ranged from 4.8-fold (DENV-
1) to 8.1-fold (DENV-3) post-dose 2 and from 6.1-fold (DENV-1) to
8.0-fold (DENV-3) post-dose 3. Post-dose 2 and 3 GMTs were higher
in the FV-seropositive group. Post-dose 3 GMTs showed a greater
increase in the FV-seronegative group than in the FV-seropositive
group. Pre-vaccination and post-dose 3 GMTs were higher in par-
ticipants who were seropositive for dengue disease at baseline than
in participants who  were seronegative, regardless of JE serostatus.
Post-dose 3 GMTs were slightly higher in JE seropositive partici-
pants versus JE seronegative participants. However, this difference
was  not signiﬁcant. The highest post-dose 3 GMTs were observed in
participants who  were seropositive for both dengue disease and JE
at baseline. Robust immune responses were also reported regard-
less of age, although post-dose 2 and 3 GMTs were higher in 6–11
year-olds compared with 2–5 year-olds (Table 2).
The post dose 2 and 3 antibody reverse cumulative distribu-
tion curves demonstrated good similarity of responses (curves close
together and parallel, Fig. 3).In FV-seronegative children, the dose
3 vaccination increased the overall neutralizing titres with a left
shift of the curves for serotypes 1 and 2.
4. Discussion
CYD-TDV is in advanced stages of clinical development and
large Phase III efﬁcacy studies are underway in Latin America
(NCT01374516) and Asia (NCT01373281); no other dengue disease
candidate vaccine has reached this stage of development to date. As
the ﬁrst paediatric trial to use Phase III CYD-TDV lots manufactured
using large-scale processes, the present study is a key component
of the global clinical trial programme for CYD-TDV [17–19]. Results
showed that CYD-TDV had a satisfactory safety proﬁle and gen-
erated a balanced humoral immune response against DENV1–4 in
this paediatric population.
All four DENV serotypes circulate in Malaysia and their relative
geographic distributions vary over time [11]. Baseline seroposi-
tivity against DENV1–4 was similar in both groups, which was
expected, given that dengue disease is endemic in Malaysia.
The safety proﬁle of CYD-TDV was satisfactory for the total pop-
ulation and in the subsets analyzed. Reactogenicity decreased with
subsequent doses of CYD-TDV, consistent with observations from
previous phase I and II studies [11]. Injection site erythema and
swelling were reported frequently, but at Grade 1 intensity and at
similar rates in both treatment groups. Reactogenicity was similar
in the subsets of FV-serostatus and age ranges and in the whole
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Tig. 2. Proportion of participants with different categories of adverse events and ad
n  the CYD-TDV Group by FV-serostatus at baseline and (C) in children stratiﬁed by
opulation, without increased reactogenicity in 2–5 year-olds, or
aseline FV-seropositive children compared with 6–11-year-olds
r FV-seronegative children. The favourable safety and reactogen-
city results observed are similar to those from previous Phase I
nd II studies [20–29]. Our data from Malaysia are consistent with
hose reported from 2 to 11-year olds in Peru [22] and Singapore
26], from 4 to 11-year olds in Thailand [29] and from 9 to 16-year
lds in Latin America [28].
The three-dose regimen of CYD-TDV elicited a good immune
esponse in terms of GMTs, regardless of FV-serostatus or age
roup. GMTs increased both post-dose 2 and 3 in the overall
opulation. The robust and balanced antibody responses against
ENV1–4 were similar to those reported in other studies of CYD-
DV in children [22,26,28]. However, the results of the Phase IIb reactions after each vaccination: Safety Analysis Set for (A) all participants and (B)
–5 and 6–11 years). AE, adverse event; FV, ﬂavivirus.
proof-of-concept efﬁcacy study by Sabchereon et al. challenged the
hypothesis that such a robust, balanced antibody response proﬁle,
as assessed by PRNT50, translates to similar levels of protection
against all viruses of each DENV serotype [29]. The higher GMTs
reported after vaccination in the FV-seropositive group compared
with the FV-seronegative group were also observed in children vac-
cinated in Latin America [28]. The third dose had little impact in the
FV-seropositive group but was  more marked in the FV-seronegative
group. Therefore, in the context of a mixed population with both
FV-seropositive and FV-seronegative children, a three-dose regi-
men is beneﬁcial to induce a balanced immune response. Baseline
serostatus for dengue disease but not for JE had an impact on post-
dose 3 GMTs. However, it should be noted that the sample size
of this subset was  limited-only 67 participants in the CYD-TDV
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roup and 17 participants in the placebo group were seropositive
or JE antibodies (PRNT50 titre ≥ 10 l/dil). The immune response
n the current study was satisfactory in both age groups, although
igher GMTs were reported in those aged 6–11-years olds than
–5-year olds post-dose 2 and 3. This observation was  probably
he result of the difference in baseline DENV serostatus between the
wo age groups (difference in pre-vaccination GMTs for DENV1–4)
s the main driver for vaccine immunogenicity. The link between
aseline FV-serostatus and age range on the immune response is
resumed to be the result of a longer period of exposure to nat-
ral dengue infection in the 6–11 years group compared with the
ounger cohort.
Although the highest attack rate for dengue infection is com-
only observed in young adults aged 20–24 years old [34], the large
roportion of children who were seropositive at baseline for at least
ne DENV serotype indicates that dengue disease is endemic and
nfects children in Malaysia at a young age. However, no suspected
ases of dengue disease requiring hospitalization were reported by
he investigators or participants’ parents in this study and antibody
itres in the placebo group did not increase, suggesting the absence
r very limited circulation of wild-type DENV strains in this pop-
lation during the study period. Therefore, the results of vaccine
mmunogenicity were probably not biased by natural dengue infec-
ions. However, the placebo group was small and conclusions based
n these results need to be kept in context.s for DENV serotypes 1–4 by baseline FV-serostatus, pre-vaccination and after two
 plaque reduction neutralization test.
This study was not designed to assess CYD-TDV efﬁcacy and did
not address long-term vaccine safety or immune persistence, with
follow-up limited to 6 months. However, large Phase III efﬁcacy
studies are underway and long-term follow-up is ongoing in these
studies, as well as in other Phase I [20] and Phase II studies [29].
Furthermore, the sample size of this study was too small to accu-
rately analyze any potential priming effect of previous exposure to
individual FV subtypes (e.g. JE).
5. Conclusion
In conclusion, this Phase III study demonstrated a satisfactory
safety proﬁle and a balanced humoral immune response against
DENV1–4 for CYD-TDV administered via a three-dose regimen to
children in Malaysia living in an area where dengue disease is
endemic.
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